A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors
This is a Phase 1, open label, multi center, dose escalation and expansion, safety, tolerability, PK, and pharmacodynamics study of PF 06939999 in previously treated patients with advanced or metastatic cancer.
Checked against the public recordLast updated Jan 13, 2025 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Pfizer
- Interventions being studied
- Drug: PF-06939999 dose escalation; Drug: PF-06939999 monotherapy; Drug: PF-06939999 in combination with docetaxel
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Histologically or cytologically confirmed locally advanced or metastatic NSCLC, urothelial carcinoma or HNSCC * Progressed after at least 1 line of treatment and no more than 3 lines of treatment * At least one measurable lesion as defined by RECIST version 1.1 * ECOG Performance Status 0 or 1 * Adequate Bone Marrow Function * Adequate Renal Function * Adequate Liver Function * Resolved acute effects of any prior therapy Exclusion Criteria: * Known active uncontrolled or symptomatic CNS metastases. * Major surgery, radiation therapy, systemic anti-cancer therapy or investigational drug(s) within 4 weeks prior to study entry. * Active, uncontrolled infection, including COVID-19 * Known or suspected hypersensitivity to PF-06939999 * Inability to consume or absorb study drug
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Scottsdale Healthcare Hospitals d/b/a HonorHealthScottsdale, Arizona
- Virginia G. Piper Cancer PharmacyScottsdale, Arizona
- Keck Hospital of USCLos Angeles, California
- LAC + USC Medical CenterLos Angeles, California
- USC Norris Comprehensive Cancer CenterLos Angeles, California
- USC/Norris Comprehensive Cancer CenterLos Angeles, California
- Keck Medical Center of USC PasadenaPasadena, California
- AdventHealth Celebration Infusion CenterCelebration, Florida
- AdventHealth Medical Group Oncology Research at CelebrationCelebration, Florida
- University Of Miami Hospital and Clinics/Sylvester Comprehensive Cancer CenterMiami, Florida
- AdventHealth Orlando - Investigational Drug ServicesOrlando, Florida
- AdventHealth Orlando Infusion CenterOrlando, Florida
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 13, 2025. Always confirm current availability with the study team.